UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 81

Sortiert nach

Endometrial fluid is a specific and non-invasive biological sample for protein biomarker identification in endometriosis

Human reproduction (Oxford), 2009-04, Vol.24 (4), p.954-965

2009

Link zum Volltext

Verfügbarkeit prüfen

P384 Therapeutic drug monitoring: performance of the first lateral flow-based Point of Care test for the quantification of infliximab in a finger prick

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S396-S397

2021

Link zum Volltext

Verfügbarkeit prüfen

Letter: immunogenicity of infliximab originator vs. CT‐P13 in IBD patients

Alimentary pharmacology & therapeutics, 2017-11, Vol.46 (9), p.903-905

2017

Link zum Volltext

Verfügbarkeit prüfen

Response to: Comparison of infliximab drug measurement across three commercially available ELISA kits

Pathology, 2017-04, Vol.49 (3), p.332-334

2017

Link zum Volltext

Verfügbarkeit prüfen

FRI0212 Comparison Study of Tests Available To Monitor Tocilizumab Therapy in Rheumatic Patients

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.508-508

2016

Link zum Volltext

Verfügbarkeit prüfen

AB0656 Clinical Relevance of Measuring Free versus Total Anti-Infliximab Antibodies in Patients with Spondyloarthritis

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.1128-1129

2016

Link zum Volltext

Verfügbarkeit prüfen

SAT0125 Association of Rituximab Levels to Clinical Response and B Cell Recovery in Rheumatoid Arthritis Patients

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A623-A623

2013

Link zum Volltext

Verfügbarkeit prüfen

Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis

Rheumatology (Oxford, England), 2011-08, Vol.50 (8), p.1445-1452

2011

Link zum Volltext

Verfügbarkeit prüfen

Comparison of percutaneous tracheostomy methods in intensive care patients: blind, fibreoptic bronchoscopy and fibreoptic bronchoscopy plus ultrasound

British journal of anaesthesia : BJA, 2018-07, Vol.121 (1), p.e12-e13

2018

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of antiasthmatic activity of Cassia sophera linn

Pharmacognosy Magazine, 2009-07, Vol.5 (19), p.109

2009

Link zum Volltext

Verfügbarkeit prüfen

P337 Therapeutic drug monitoring: standardization of Promonitor Quick IFX and Promonitor Quick ADL point of care tests with WHO International Standards for the quantification of infliximab and adalimumab in whole blood and serum

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i353-i354

2022

Link zum Volltext

Verfügbarkeit prüfen

P851 Therapeutic drug monitoring of infliximab and adalimumab versus clinical control during maintenance therapy in patients with Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1580-i1580

2024

Link zum Volltext

Verfügbarkeit prüfen

P329 Adalimumab therapeutic drug monitoring test validated for measuring ABP 501 biosimilar

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S265-S266

2019

Link zum Volltext

Verfügbarkeit prüfen

P431 Validation of a therapeutic drug monitoring test to measure the adalimumab biosimilar SB5 in comparison with the reference adalimumab

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S324-S324

2019

Link zum Volltext

Verfügbarkeit prüfen

P387 Infliximab therapeutic drug monitoring test validated for measuring CT-P13 and SB2 biosimilars

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S299-S299

2018

Link zum Volltext

Verfügbarkeit prüfen

P342 Correlation of the first lateral flow-based Point of Care test to quantify infliximab and anti-infliximab antibodies in a finger prick sample with the reference ELISA technique

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S366-S366

2021

Link zum Volltext

Verfügbarkeit prüfen

P554 Point of Care detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the biosimilar SB2: performance comparison with ELISA

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S391-S391

2019

Link zum Volltext

Verfügbarkeit prüfen

PTU-087 Therapeutic cut-off of infliximab in patients with inflammatory bowel diseases

Gut, 2015-06, Vol.64 (Suppl 1), p.A99-A99

2015

Link zum Volltext

Verfügbarkeit prüfen

P546 Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S387-S387

2019

Link zum Volltext

Verfügbarkeit prüfen

PrP polymorphisms in Basque sheep breeds determined by PCR-restriction fragment length polymorphism and real-time PCR

Veterinary record, 2004-06, Vol.154 (23), p.717-722

2004

Link zum Volltext

Verfügbarkeit prüfen

P548 Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S466-S467

2020

Link zum Volltext

Verfügbarkeit prüfen

PTU-088 Method comparison study of assays for the determination of infliximab, adalimumab, and anti-drug antibody levels in patients with inflammatory bowel diseases

Gut, 2015-06, Vol.64 (Suppl 1), p.A99-A100

2015

Link zum Volltext

Verfügbarkeit prüfen

P607 Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade®) to the biosimilar SB2 (Flixabi®) in inflammatory bowel disease patients

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S416-S416

2018

Link zum Volltext

Verfügbarkeit prüfen

P633 Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S403-S404

2017

Link zum Volltext

Verfügbarkeit prüfen

P475 Switching from infliximab originator to CT-P13 is not related to increased immunogenicity in IBD patients: a prospective case-control study

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S320-S320

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 81

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Full Text

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(79)

Publikationsform

Artikel
(80)
Berichte
(1)

Sprache

Englisch
(81)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Endometrial fluid is a specific and non-invasive biological sample for protein biomarker identification in endometriosis

P384 Therapeutic drug monitoring: performance of the first lateral flow-based Point of Care test for the quantification of infliximab in a finger prick

Letter: immunogenicity of infliximab originator vs. CT‐P13 in IBD patients

Response to: Comparison of infliximab drug measurement across three commercially available ELISA kits

FRI0212 Comparison Study of Tests Available To Monitor Tocilizumab Therapy in Rheumatic Patients

AB0656 Clinical Relevance of Measuring Free versus Total Anti-Infliximab Antibodies in Patients with Spondyloarthritis

SAT0125 Association of Rituximab Levels to Clinical Response and B Cell Recovery in Rheumatoid Arthritis Patients

Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis

Comparison of percutaneous tracheostomy methods in intensive care patients: blind, fibreoptic bronchoscopy and fibreoptic bronchoscopy plus ultrasound

Evaluation of antiasthmatic activity of Cassia sophera linn

P337 Therapeutic drug monitoring: standardization of Promonitor Quick IFX and Promonitor Quick ADL point of care tests with WHO International Standards for the quantification of infliximab and adalimumab in whole blood and serum

P851 Therapeutic drug monitoring of infliximab and adalimumab versus clinical control during maintenance therapy in patients with Inflammatory Bowel Disease

P329 Adalimumab therapeutic drug monitoring test validated for measuring ABP 501 biosimilar

P431 Validation of a therapeutic drug monitoring test to measure the adalimumab biosimilar SB5 in comparison with the reference adalimumab

P387 Infliximab therapeutic drug monitoring test validated for measuring CT-P13 and SB2 biosimilars

P342 Correlation of the first lateral flow-based Point of Care test to quantify infliximab and anti-infliximab antibodies in a finger prick sample with the reference ELISA technique

P554 Point of Care detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the biosimilar SB2: performance comparison with ELISA

PTU-087 Therapeutic cut-off of infliximab in patients with inflammatory bowel diseases

P546 Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease

PrP polymorphisms in Basque sheep breeds determined by PCR-restriction fragment length polymorphism and real-time PCR

P548 Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study

PTU-088 Method comparison study of assays for the determination of infliximab, adalimumab, and anti-drug antibody levels in patients with inflammatory bowel diseases

P607 Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade®) to the biosimilar SB2 (Flixabi®) in inflammatory bowel disease patients

P633 Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease

P475 Switching from infliximab originator to CT-P13 is not related to increased immunogenicity in IBD patients: a prospective case-control study

Aktive Filter

Suchergebnisse filtern